Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + quavonlimab + vibostolimab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a **combination immunotherapy** regimen comprising three monoclonal antibodies: **pembrolizumab**, a programmed cell death protein 1 (PD-1) inhibitor; **quavonlimab**, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor; and **vibostolimab**, a T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor. Each antibody blocks a distinct immune checkpoint pathway, collectively aiming to restore and enhance T cell-mediated anti-tumor immunity by simultaneously preventing immune exhaustion (PD-1), suppressing regulatory T cell activity (CTLA-4), and antagonizing innate and adaptive immune suppression (TIGIT). Development is led by **Merck**. The triplet is principally tested in advanced solid tumors, including melanoma, non-small cell lung cancer (NSCLC), and others, within the KEYMAKER and KEYVIBE clinical trial programs[2][4].
- Other names
- pembrolizumab + quavonlimab + vibostolimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on pembrolizumab + quavonlimab + vibostolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + quavonlimab + vibostolimab.